The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 22nd 2024
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.
Allovectin Falters in Late-Stage Melanoma Trial
Nearly two decades after clinical trials began, the investigational immunotherapy Allovectin failed to meet key endpoints in a phase III trial in patients with stage III/IV metastatic melanoma and will no longer be developed.
T-VEC Delivers Durable Responses in Unresectable Melanoma
July 31st 2013T-VEC manifested significant gains in durable response rate and other key clinical indicators in patients with advanced melanoma in what researchers described as the first phase III trial demonstrating the efficacy of an oncolytic virus immunotherapy.
Intermittent Dosing May Overcome Resistance to Vemurafenib in Patients With Melanoma
Using an intermittent dosing strategy with vemurafenib, instead of continuous dosing, has the potential to overcome the development of resistance in patients with melanoma treated with the drug.
Dr. Weber Explores Nivolumab in Advanced Melanoma
June 21st 2013Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.
The Future of Melanoma Treatment
June 6th 2013Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.
GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma
Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.
Dabrafenib and Trametinib Both Approved for Advanced Melanoma
The FDA approved both dabrafenib and trametinib for the treatment of patients with metastatic or unresectable melanoma, as well as a companion diagnostic to properly identify the patients exhibiting the mutations that are targeted by these agents.
Early Results Robust for New PD-L1 Immunotherapy Agent
May 15th 2013An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.
PD-1 Targeted Antibody Lambrolizumab Receives FDA Breakthrough Designation
Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.